 |
|
|
| |
No pharmacokinetic interaction between the investigational HCV protease inhibitor simeprevir (TMC435) and an oral contraceptive containing ethinylestradiol and norethindrone
|
| |
| |
Reported by Jules Levin
63rd Annual Meeting
of the American Association for the Study
of Liver Diseases (AASLD)
Boston, MA, USA · November 9-13, 2012
S Ouwerkerk-Mahadevan,1 A Simion,2 K Spittaels,2 M Peeters,2 M Beumont-Mauviel2
1Janssen Research and Development, Beerse, Belgium; 2Janssen Infectious Diseases, Beerse, Belgium
|
| |
|
|
|
|
|
